While buying right now may be too risky for the average investor, the small-cap biotech highlighted in today’s article could be worth keeping an eye on, even as it (and many other promising biotech stocks) may have slipped under the radar as attention has shifted to potential COVID-19 plays (which this stock is not). Why? The company’s drug candidate for NASH, a severe form of non-alcoholic fatty liver disease, has posted impressive clinical trial results – and, if ultimately successful, “needs only to gobble up a small portion of the total NASH market to become a mega-blockbuster.” For more, CLICK HERE.
